Spontaneously diabetic Torii Leprfa (SDT fatty) rat: A novel model of obese type 2 diabetes

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 30-36

  Fukuda, Sumiaki ^a   Miyajima, Katsuhiro ^a   Sasase, Tomohiko ^a   Ohta, Takeshi ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Diabetes; Diabetic complication; Dipeptidyl peptidase 4; SDT fatty rat; SDT rat

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; JTP 76209; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONGENIC STRAIN; DIABETIC NEPHROPATHY; DIABETOGENESIS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GLYCEMIC CONTROL; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT STRAIN; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SPONTANEOUSLY DIABETIC TORII RAT; WEIGHT CHANGE;

EID: 80455157971     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010030     Document Type: Article

References (15)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.
2. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-33.
3. Masuyama T, Katsuda Y, Shinohara M. A novel model of obesity-related diabetes: introgression of the Lepr(fa) allele of the Zucker fatty rat into nonobese Spontaneously Diabetic Torii (SDT) rats. Exp Anim 2005; 54: 13-20.
4. Ishii Y, Ohta T, Sasase T, et al. Pathophysiological analysis of female Spontaneously Diabetic Torii fatty rats. Exp Anim 2010; 59: 73-84.
5. Matsui K, Ohta T, Oda T, et al. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp Anim 2008; 57: 111-21.
6. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1: 89-100.
7. Hostetter TH. Diabetic nephropathy. Metabolic versus hemodynamic considerations. Diabetes Care 1992; 15: 1205-15.
8. Matsui K, Ohta T, Morinaga H, et al. Effects of preventing hyperphagia on glycolipid metabolic abnormalities in Spontaneously Diabetic Torii fatty rats. Anim Sci J 2008; 79: 605-13.
9. Morinaga H, Ohta T, Matsui K, et al. Effect of food restriction on adipose tissue in spontaneously diabetic Torii fatty rats. Exp Diabetes Res 2009; 2009: 715057.
10. Shibata T, Matsui K, Nagao K, et al. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 1999; 364: 211-9.
11. Shibata T, Takeuchi S, Yokota S, et al. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000; 130: 495-504.
12. Deacon CF. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007; 9 Suppl 1: 23-31.
13. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Op in Investig Drugs 2008; 17: 845-53.
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
15. Matsui K, Oda T, Nishizawa E, et al. Pancreatic function of spontaneously diabetic torii rats in pre-diabetic stage. Exp Anim 2009; 58: 363-74.